Brookfield Corp’s Krystal Biotech KRYS Stock Holding History

Brookfield Corp’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-5,133	Closed	-$407K	–	725
2022 Q4	$407K	Buy	+5,133	New	+$381K	﹤0.01%	547

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Brookfield Corp's KRYS Position: Q1 2023 in Review

Brookfield Corp sold out of Krystal Biotech (KRYS) in Q1 2023, closing a stake of 5,133 shares — an estimated $407K sold.

Brookfield Corp first reported a position in KRYS in Q4 2022 and held it in 1 quarter. The position peaked at $407K in Q4 2022. 160 funds tracked by Wall St. Rank hold KRYS as of Q1 2023.

Brookfield Corp reported no remaining Krystal Biotech position as of Q1 2023 after selling out during the quarter.
Brookfield Corp sold 5,133 Krystal Biotech shares in Q1 2023, an estimated $407K.
Brookfield Corp first reported a position in Krystal Biotech in Q4 2022 and held it in 1 quarter.
Brookfield Corp's Krystal Biotech position peaked at $407K in Q4 2022.
160 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2023.

Based on Brookfield Corp's 13F filing for Q1 2023, filed 15 May 2023.